Painreform Stock Today
| PRFX Stock | USD 2.75 0.03 1.10% |
Performance1 of 100
| Odds Of DistressLess than 46
|
Painreform is trading at 2.75 as of the 28th of November 2024; that is 1.10 percent increase since the beginning of the trading day. The stock's open price was 2.72. Painreform has 46 percent odds of going through some form of financial distress in the next two years and did not have a very good performance for investor during the last 90 trading days. Equity ratings for Painreform are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of October 2024 and ending today, the 28th of November 2024. Click here to learn more.
PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel. The company has 590.62 K outstanding shares of which 121.08 K shares are at this time shorted by private and institutional investors with about 0.36 trading days to cover. More on Painreform
Moving against Painreform Stock
Valuation
Check how we calculate scores
Painreform Stock Highlights
Painreform (PRFX) is traded on NASDAQ Exchange in USA. It is located in 65 Yigal Alon St., Tel Aviv, Israel, 6744316 and employs 7 people. Painreform is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 1.61 M. Painreform conducts business under Biotechnology sector and is part of Health Care industry. The entity has 590.62 K outstanding shares of which 121.08 K shares are at this time shorted by private and institutional investors with about 0.36 trading days to cover.
Painreform currently holds about 13.85 M in cash with (6.68 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.3.
Check Painreform Probability Of Bankruptcy
Ownership AllocationRoughly 92.79 pct. of Painreform outstanding shares are held by general public with 2.51 % owned by insiders and only 4.7 (%) by third-party entities.
Check Painreform Ownership Details
Painreform Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. Painreform market risk premium is the additional return an investor will receive from holding Painreform long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0268 | |||
| Jensen Alpha | 0.6337 | |||
| Total Risk Alpha | (2.93) | |||
| Sortino Ratio | 0.0338 |
Painreform Stock Against Markets
Painreform Corporate Management
| Sigal Aviel | Chief Officer | Profile | |
| Rita Keynan | Vice Operations | Profile | |
| MBA MBA | CEO CFO | Profile | |
| Pr Hazum | CTO Director | Profile | |
| Stephen DMD | Executive Development | Profile |
Additional Tools for Painreform Stock Analysis
When running Painreform's price analysis, check to measure Painreform's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Painreform is operating at the current time. Most of Painreform's value examination focuses on studying past and present price action to predict the probability of Painreform's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Painreform's price. Additionally, you may evaluate how the addition of Painreform to your portfolios can decrease your overall portfolio volatility.